Abstract:Background Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. Methods The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p < 1 x 10(-5)) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. Findings The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1.37 x 10(-8)], rs1471786 in SLC1A1 [p=1.77 x 10(-8)], and rs9291547 in PCDH7 [p=4.48x 10(-8)]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p < 0.05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1.40 x 10(-9)], rs1471786 in SLC1A1 [p=2.33 x 10(-9)], rs9291547 in PCDH7 [p=3.24 x rs9291547 in PCDH7 [p=3.24 x 10(-9)], rs12711680 in CNTNAP5 [p=2.12 x 10(-9)], and rs6444970 in TNIK [p=4.85 x 10(-8)]).], rs12711680 in CNTNAP5 [p=2.12 x 10(-8)], and rs6444970 in TNIK [p=4.85 x 10(-8)]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1.10 x 10(-8)), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4.40 x 10(-8)), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2.58 x 10(-8)). Interpretation We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia.

Genetic determinants of antidepressant and antipsychotic drug response

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Genetic factors and symptom dimensions associated with antidepressant treatment outcomes: clues for new potential therapeutic targets?

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Genome-wide meta-analyses of non-response to antidepressants identify novel loci and potential drugs

Shared polygenic susceptibility to treatment response in severe affective and psychotic disorders: Evidence from GWAS data sets

Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms

Genetics of Response to Cognitive Behavior Therapy in Adults with Major Depression: a Preliminary Report

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.

A genetic risk score to predict treatment nonresponse in psychotic depression

Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study

Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP

Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response

Five Novel Loci Associated with Antipsychotic Treatment Response in Patients with Schizophrenia: a Genome-Wide Association Study

Combining machine learning algorithms for prediction of antidepressant treatment response

Genomic predictors of response to antidepressants in Major depressive disorder (MDD): A GWAS-Based Study on Indian cohort

Which can Predict the Outcome of Antidepressants: Metabolic Genes or Pharmacodynamic Genes?

Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits

Genetic Correlates of Treatment-Resistant Depression: Insights from Polygenic Scores Across Cognitive, Temperamental, and Sleep Traits in the All of US cohort

Refining antipsychotic treatment strategies in schizophrenia: discovery of genetic biomarkers for enhanced drug response prediction